Immunity Pharma Ltd. (IPL) is a drug development company that uses novel immune and signaling-based approaches to develop therapies for inflammatory and degenerative diseases.
IPL’s drugs are peptides with biologic activity that augments natural self-repair processes utilized by the immune system itself.
IPL’s drugs have been discovered in the laboratory of Prof. Irun R. Cohen at the Weizmann Institute of Science.
IPL’s strategy is to go with nature: We develop peptides that interact with natural regulatory mechanisms to restore healthy homeostasis. For example, we do not attempt to overpower the inflammatory process, but rather modulate its behavior using its own chemical language.
Therefore our peptides are designed to be more effective than standard approaches to neuro-degeneration, and yet safer than standard approaches to immune suppression.
Since 2003 bio-medical entrepreneur and Biotech CEO. Manages IPL since its inception in 2007. Former high-tech roles include: Senior Product Director at Comverse, CEO of Cellguide, Founder of Lavi Medical, Senior Manager at Servisoft. Additional managerial, entrepreneurial and academic experience.
President and CEO of Dynamix Pharmaceuticals, signed a major licensing deal with Teva; Founder & CSO of Predix/Epix Pharmaceuticals, Led discovery of 4 novel drugs, all in Phase II clinical trials, created business alliances with GSK and Amgen (value: $1.5B), Formerly professor at Harvard & Tel-Aviv Universities.
Founder and CEO of VacciGuard, worked in the Innovative R&D division at Teva Pharmaceutical Industries for 12 years, re-established and headed the new projects unit of the firm. Was the CEO of Metabogal (now Protalix) and a partner in the Pontifax Investment Fund.
IPL is committed to state of the art drug development, employing the latest approaches in clinical drug development aimed at specific disease targets. The IPL Advisory Board plays a key role in advising the company’s clinical programs and overseeing the clinical development process. Members of our Clinical Advisory Board are:
His laboratory discovered and developed the anti-apoptosis Stressin-1 peptide (IPL344) in the course of studies of the aberrant regulation of apoptosis in lupus. Long-term experience in chronic inflammatory and degenerative diseases and in translating pre-clinical research to clinical applications:
Dr. Appel is a native of Massachusetts and received his Bachelor Degree at Harvard University and his Medical Degree from Columbia College of Physicians and Surgeons. He is Director of the MDA/ALS Research and Clinical Center at the Methodist Neurological Institute, and past Director of a National Institute of Aging Alzheimer’s Disease Research Center.
Dr. Brown graduated from Harvard Medical School and completed his doctoral training in neurophysiology at Oxford University. Dr. Brown trained in Neurology at the Massachusetts General Hospital. In 1984, The Day Neuromuscular Research Laboratory was founded by Dr. Brown to investigate neuromuscular diseases, including Miyoshi myopathy and ALS.
Dr. Brown’s laboratory has focused on the identification of gene defects that elucidate the molecular pathogenesis of selected neuromuscular diseases including amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), muscular dystrophy, adrenoleukodystrophy, hereditary neuropathy and hyperkalemic periodic paralysis. Knowledge of theses disease genes has facilitated the creation of mouse and cell-based models of these disorders. In turn, these resources have allowed study of therapeutic strategies using conventional small molecule approaches and new modalities such as inhibitory RNAi.